Intro

This chapter explores the financial connections between pharmaceutical companies and healthcare providers, revealing a staggering $8 billion in non-research payments made to U.S. physicians from 2020 to 2023. It raises critical concerns about how these ties may affect prescribing practices and ultimately impact patient care.